Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1640547 | 0.89 | HPGD (0.74) | CA12CA1CA2CA9HPGD | |
| SCHEMBL2830503 | 0.86 | HPGD (0.65) | CA12CA1CA2CA9HPGD | |
| SCHEMBL27469554 | 0.82 | CA12 (0.68) | CA12CA1CA2CA9HPGD | |
| SCHEMBL17799216 | 0.82 | CA12 (0.68) | CA12CA1CA2CA9HPGD | |
| Methane SCHEMBL11244066 | 0.82 | CA12 (0.58) | CA12CA1CA2CA9HPGD | |
| SCHEMBL4529538 | 0.82 | CA12 (0.60) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL11410911 | 0.81 | CA12 (0.53) | CA12CA1CA2CA9HPGD | |
| SCHEMBL6210691 | 0.81 | HPGD (0.64) | CA12CA1CA2CA9HPGD | |
| SCHEMBL863140 | 0.81 | CA12 (0.66) | CA12CA1CA2CA9HPGD | |
| SCHEMBL1461242 | 0.81 | GAA (0.60) | CA12CA1CA2CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510413-A | DCLK1 kinase inhibitor and preparation method and application thereof | 杭州医学院 | 2024-02-06 | — | — | CN | claimed |
| CN-107189197-B | Comprehensive conveying pipe for high-strength insulating flame-retardant pipeline gallery | 上海中塑管业有限公司 | 2020-05-12 | — | — | CN | claimed |
| CN-106220994-B | A kind of high intensity PP-RCT anti-flaming tubular products and preparation method | 刘志光 | 2018-06-01 | — | — | CN | claimed |
| CN-106220994-A | A kind of high intensity PP RCT anti-flaming tubular product and preparation method | 刘志光 | 2016-12-14 | — | — | CN | claimed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | claimed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | claimed |
| CN-117510413-A | DCLK1 kinase inhibitor and preparation method and application thereof | 杭州医学院 | 2024-02-06 | — | — | CN | disclosed |
| US-11814366-B2 | Antiviral compounds and use thereof | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2023-11-14 | — | — | US | disclosed |
| EP-3765454-B1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIV DEGLI STUDI DI SIENA (IT) | 2023-11-08 | — | — | EP | disclosed |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITA DEGLE STUDI DI SIENA (IT) | 2021-03-11 | — | — | US | disclosed |
| EP-3765454-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | Universita' Degli Studi di Siena (IT) | 2021-01-20 | — | — | EP | disclosed |
| CN-107189197-B | Comprehensive conveying pipe for high-strength insulating flame-retardant pipeline gallery | 上海中塑管业有限公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019175436-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | UNIVERSITÀ DEGLI STUDI DI SIENA (IT) | 2019-09-19 | — | — | WO | disclosed |
| US-6699866-B2 | FOR THERAPY OF ADDICTION, ANXIETY, DEPRESSION, SEXUAL DYSFUNCTION, HYPERTENSION, MIGRAINE, ALZHEIMER'S DISEASE, OBESITY, EMESIS, PSYCHOSIS, ANALGESIA, SCHIZOPHRENIA, PARKINSON'S DISEASE, RESTLESS LEG SYNDROME, SLEEPING DISORDERS | SEPRACOR INC. | 2004-03-02 | — | — | US | disclosed |
| CN-1437584-A | Tricyclic protein kinase inhibitors | WYETH CORP (US) | 2003-08-20 | — | — | CN | disclosed |
| WO-2003066630-A2 | QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS | AMGEN INC. (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002083863-A2 | THIAZOLE AND OTHER HETEROCYCLIC LIGANDS AND USE THEREOF | SEPRACOR, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0988301-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998056788-A1 | IMIDAZOLYL-CYCLIC ACETALS | RHONE-POULENC RORER LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814366-B2 | Antiviral compounds and use thereof | MAVS, EIF2AK2, SARS1 | CA12 2300/4885CA1 4192/4885CA2 3906/4885 |
| US-20030105071-A1 | Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof | HTR5A, OPRL1, HTR2C | CA12 4876/4885CA1 4770/4885CA2 4763/4885 |
| US-20210070737-A1 | ANTIVIRAL COMPOUNDS AND USE THEREOF | MAVS, EIF2AK2, SARS1 | CA12 2300/4885CA1 4192/4885CA2 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.